BIOTECHNICA 2007 On Course for Continuing Growth 15th International Trade Fair, Conference and Partnering for Biotechnology (9 - 11 October)

    --  This Year's Show Surpasses its Predecessor of 2005

    --  Growing International Participation

    --  Biggest Conference Program since the Inception of BIOTECHNICA

    HANNOVER, GERMANY, October 5 /CNW/ - Europe's leading trade fair for
biotechnology - is on course for continuing growth: "It's bigger, it's more
varied, and it's more international", says Stephan Ph. Kuhne, member of the
Board at Deutsche Messe in Hannover, Germany. "The new format with its four
key elements is designed to sharpen up the show's profile and enhance its
appeal." One of the high points this year is the most extensive conference
program in the history of the show. "The key issues for the biotech industry
today will be addressed by experts from 14 nations in more than 20 forums and
400 lectures. This year's visitors will discover the most exciting BIOTECHNICA
in the 22-year history of the show", claims Kuhne.

    863 exhibitors from 32 countries (2005: 849 exhibitors from 30 nations)
have booked their stands for the upcoming show, which runs from 9 to 11
October 2007 in Hannover. Their presentations will occupy a total of more than
13,000 square metres of display space, or four percent more than in 2005. "The
growth in exhibitor numbers, floor space and international appeal underlines
the fact that BIOTECHNICA is the most important European business platform for
the biotech industry", emphasizes Kuhne. This year's show will be officially
opened on 8 October by Gunter Verheugen, Vice-President of the European

    Headline themes

    So-called "drug-device combination therapies" are this year's hot topic,
with massive market growth forecast for this segment. As the name suggests,
these combine a pharmacological substance with a medical product that acts as
a delivery system. The global market for stents - tiny tubular implants that
are used to support the walls of blood vessels - is currently growing by an
average of around 11 percent a year, as a study by the American analysts at
BCC Research has shown. According to their calculations, these products will
be generating sales worth eight billion US dollars by the year 2010.

    Another major theme is the field of biomedical research known as
regenerative medicine, which encompasses stem cell research and the
cultivation of tissue and cell layers (= tissue engineering). Stem cells are
becoming increasingly important in the battle against serious and hitherto
incurable diseases, and could hold out the promise of a cure for cancer, heart
disease or autoimmune diseases.

    Another area of great interest at present is so-called "white
biotechnology", which can substantially improve industrial processes through
the use of biological molecules. Typical applications can be found in the
chemical, textile or food industries - for example, in the production of
fibres, chemicals or fuels made from starch, cellulose or vegetable oils.

    Meanwhile nanobiotechnology is also destined to play an increasingly
important role in the future in medical engineering, medical therapy and
diagnostics, as well as in pharmaceutical research. Through the use of tiny
sensors it is now possible to detect the smallest changes in biological
processes, such as a rise in protein concentrations in the human brain. This
means that diseases such as Alzheimer's, diabetes or Parkinson's can be
diagnosed and treated at a much earlier stage.

    At the same time microsystems technology is coming increasingly to the
fore in the diagnosis and treatment of diseases as well as in microsurgery and
intelligent implants. Biochips that can be used virtually anywhere enable
doctors to get diagnostic results quickly without resorting to elaborate
laboratory testing. The focus is also on plant biotechnology, food
biotechnology and environmental biotechnology. In fact, BIOTECHNICA 2007
presents the whole spectrum of biotechnology - from basic biotechnology,
bioinformatics, products and services to the five principal areas of
application - pharmaceuticals and medicine, industry, nutrition, agriculture
and the environment.

    Growing international participation

    This year 589 exhibitors from Germany will be at the show (2005: 581),
including such leading names as Sartorius, Merck and Boehringer Ingelheim.
From outside Germany a total of 274 companies will be present with stands
(2005: 268), including market leaders such as Roche, Qiagen, Perkin Elmer and
GE Healthcare. The majority of foreign companies come from Switzerland, the
United Kingdom and the USA, followed by Russia and France. There is a notable
increase this year in exhibitor numbers from immediate European neighbours
France, Austria and Switzerland. All the major biotech nations also have their
own national pavilions at the show. Other national group presentations are
coming from America and the Asian/Pacific region. The exhibitor presence at
BIOTECHNICA 2007 spans four continents in all.

    The top five Federal German states

    Baden-Wurttemberg tops the league table of German states with 103
exhibitors, followed by North Rhine-Westphalia with 93 exhibiting companies
and organizations. In third place is the "home state" Lower Saxony, with 67
exhibitors. Bavaria and Hessen rank in fourth and fifth place, with 61 and 59
exhibitors respectively.

    New four-part presentation formula

    The 15th BIOTECHNICA has far outgrown the conventional trade show format.
"Today's BIOTECHNICA is the central European platform for strategic alliances,
new business deals and knowledge transfer. It's the meeting place of choice
for international experts from science, industry and government", says Kuhne.
Underpinning this is the new four-part presentation formula: Exhibition,
Conference program - which has been greatly extended for the upcoming show -
as the most prestigious competition aimed at motivating young biotech
companies in Europe. Moreover, this year's BIOTECHNICA is taking place in
Halls 8 and 9 at the southern end of the exhibition grounds - conveniently
close to the Convention Center, where the Conference program will be staged.

    Biggest Conference program in the history of BIOTECHNICA

    This year's Conference program is the most extensive in BIOTECHNICA's
history, with no less than 20 high-powered congresses featuring over 400
lecture presentations by experts from 14 nations. The combination of
scientific lectures, the "Innovation Forum" (corporate and product
presentations by exhibiting companies) and the new BIOTECHNICA PARTNERING,
with the focus this year on "drug-device combination therapies", is an ideal
setup for companies looking for suitable joint-venture partners and
interesting business models. Decision-makers from industry, the R&D community
and venture capital companies, whose paths would not otherwise cross in the
normal course of events, are brought together here with business in mind.
Among the big names participating in the PARTNERING program are
sanofi-aventis, Novartis, Boston Scientific, GE Healthcare and

    In parallel with BIOTECHNICA, Deutsche Messe is for the first time
hosting the "German Biotechnology Days", the follow-on event to the BMBF
Biotechnology Days organized by the Federal Ministry of Education and
Research. At the "Tri-national Cluster Conference" - the first Central
European summit for the white biotechnology industry - the leading clusters in
Germany, Austria and Switzerland will be giving an overview of the key trends
and developments in this fast-growing sector. The first "German-Brazilian
Forum" is designed to promote scientific and business partnerships in the
interests of bilateral bio-business. Other topics addressed at the Conference
include regenerative medicine, plant and food biotechnology, the utilization
of biomass and nanobiotechnology. Meanwhile the "BIOTECHNICA jobvector" serves
as a valuable source of information and contacts for budding young scientists
on their way to biotech careers.

    Awards for the best new work in biotechnology

    This year Deutsche Messe will be presenting the EUROPEAN BIOTECHNICA
AWARD for the fifth time. Now worth a total of 100,000 euros, this award goes
to the three European companies judged to be the top innovators in
biotechnology and the life sciences. Prizes are given for the best new
products, services, concepts and business ideas. The winner out of the three
finalists - the biopharmaceutical company Bavarian Nordic A/S, Denmark, the
biotechnology company Genmab A/S, Denmark, and Britain's Renovo Group Plc -
will be announced at the prize-giving ceremony that takes place as part of the
official opening of BIOTECHNICA 2007 on 8 October in Hannover. The prizes will
be presented by Gunter Verheugen, Vice-President of the European Commission,
who will also deliver the inaugural address. Other speakers include the
Premier of Lower Saxony, Christian Wulff, and Dr. Karl-Ludwig Kley, Chairman
of the Board of Merck KGaA. The opening ceremony will be attended by more than
500 international guests from industry, science, R&D and government.

For further information:

For further information: DEUTSCHE MESSE AG for BIOTECHNICA Katharina
Siebert, +49 511 89-31028

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890